Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms, and Prostate Cancer Treatment and Research.
OATP2B1 Deficiency Ameliorates Irinotecan-Induced Gastrointestinal Toxicity.
Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors.
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort study.
Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017–2024): a retrospective, multicentre cohort study
The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1).
Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.
Cardiotoxicity of trametinib monotherapy in adults with neurofibromatosis type 1: Results from the TRAIN study.
Can evolutionary therapy be applied in non-small cell lung cancer?
The impact of immune checkpoint inhibitors on gonadal function in patients with solid tumors.
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale.
Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice.
Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma.
Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC After Immune Checkpoint Blockade.
Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with
<i>ALK-</i>
Positive Non-Small Cell Lung Cancer
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study
A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy.
From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology.
Implementation of model-informed precision dosing for tamoxifen therapy in patients with breast cancer: A prospective intervention study.
Pseudo acute kidney injury in patients receiving CDK4/6 inhibitors.
The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study.
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials.
Onset and progression of atherosclerosis in patients with melanoma treated with immune checkpoint inhibitors.
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.
Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study.
New metabolic insights into the mechanism of ifosfamide encephalopathy.
Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type.
Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B).
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC.
Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors.
Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial.